Skip to content

A single-center, single-arm safety study of tympanometric injection of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) in the treatment of refractory sudden deafness.

A single-center, single-arm safety study of tympanometric injection of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles (hucMSC-sEVs) in the treatment of refractory sudden deafness.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103765
Enrollment
Unknown
Registered
2025-06-05
Start date
2025-06-24
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden deafness

Interventions

Test Group 3:For 5 consecutive days, inject 0.3ml of hucMSC sEVs into the tympanic cavity daily. 4×10^9 particle/ml
Test Group 4:For 5 consecutive days, inject 0.3ml of hucMSC sEVs into the tympanic cavity daily. 8×10^8 particle/ml
Test Group 2:For 5 consecutive days, inject 0.3ml of hucMSC sEVs into the tympanic cavity daily. 2×10^10 particle/ml
Test Group 1:For 5 consecutive days, inject 0.3ml of hucMSC sEVs into the tympanic cavity daily. 10^11 particle/ml

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The subject voluntarily cooperated with the study and signed the informed consent form; 2. Male or female, age = 18 years; 3. Meet the diagnostic criteria for sudden onset sensorineural hearing loss within 72 hours, hearing loss at least two adjacent frequencies = 20dBHL; After receiving more than 7 days of conventional treatment with glucocorticoids, the average pure-tone hearing threshold improvement of the hearing loss frequency is less than 15 dB, and the average pure tone hearing threshold is greater than 60 dBHL before treatment; 4. Acoustic neuroma was excluded by magnetic resonance examination, and no clear cause (including systemic or local factors) was found.

Exclusion criteria

Exclusion criteria: 1. Acute or chronic infectious inflammation, tympanic membrane perforation, tympanic effusion, and middle ear cholesteatoma in the middle ear on the affected side; 2. acoustic neuroma or other central nervous system disease that causes hearing loss; 3. Other circumstances judged by the investigator to be unsuitable for inclusion; 4. exclude pregnant and lactating patients; 5. Those who are allergic to drugs.

Design outcomes

Primary

MeasureTime frame
Pure-tone hearing threshold audiometry;

Secondary

MeasureTime frame
Pure-tone hearing threshold audiometry;

Countries

China

Contacts

Public ContactZhang Hongzheng

Zhujiang Hospital of Southern Medical University

zhanghongzheng@vip.163.com+86 20 61643064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026